Stochastic fluctuations on the transcriptional stage contribute to isogenic cell-to-cell heterogeneity in mammalian cell populations. Nevertheless, we nonetheless don’t have any clear understanding of the repercussions of this heterogeneity, given the dearth of instruments to independently management imply expression and variability of a gene. Right here, we engineer an artificial circuit to modulate imply expression and heterogeneity of transgenes and endogenous human genes.
The circuit, a Tunable Noise Rheostat (TuNR), consists of a transcriptional cascade of two inducible transcriptional activators, the place the output imply and variance may be modulated by two orthogonal small molecule inputs. On this trend, totally different combos of the inputs can obtain the identical imply however with totally different inhabitants variability.
With TuNR, we obtain low basal expression, over 1000-fold expression of a transgene product, and as much as 7-fold induction of the endogenous gene NGFR. Importantly, for a similar imply expression stage, we’re in a position to set up various levels of heterogeneity in expression inside an isogenic inhabitants, thereby decoupling gene expression noise from its imply. TuNR is subsequently a modular instrument that can be utilized in mammalian cells to allow direct interrogation of the implications of cell-to-cell variability.
Intracellular matrix metalloproteinase-9 mediates epigenetic modifications and autophagy to manage differentiation in human cardiac stem cells
Epigenetic reprogramming and autophagy have crucial roles in differentiation of stem cells. Nevertheless, little or no is thought about how epigenetic modifications are mediated and the way they contribute to autophagy and differentiation in human cardiac stem cells (hCSCs). Beforehand, we’ve got reported that intracellular matrix metalloproteinase-9 (MMP9), a collagenase, mediates cell dying in hCSCs.
Right here, we investigated whether or not intracellular MMP9 mediates epigenetic modifications and autophagy in hCSCs. We created MMP9KO hCSCs and handled them with 5-azacytidine, an inhibitor of DNA methylation, and bafilomycin A1, an inhibitor of autophagosome degradation, and evaluated epigenetic modifications, autophagic flux, and differentiation.
Our outcomes confirmed compromised epigenetic modifications, lowered autophagy, and impaired differentiation in MMP9KO hCSCs. Remarkably, paracrine MMP9 supplementation restored epigenetic modifications however additional lowered autophagy in MMP9KO hCSCs. We conclude that intracellular MMP9 is a crucial mediator of epigenetic modifications and autophagy in hCSCs. Moreover, the endocrine and paracrine results of MMP9 differ for regulating autophagy in hCSCs. These novel roles of MMP9 are precious for stem cell remedy.
Strengthened Poly(ε-caprolactone) Bimodal Foams through Phospho-Calcified Cellulose Nanowhisker for Osteogenic Differentiation of Human Mesenchymal Stem Cells
On this work, phospho-calcified cellulose nanowhiskers (PCCNWs) have been ready from wastepaper powder (WPP) and have been dispersed in poly(ε-caprolactone) (PCL). The biocompatible and biodegradable (PCL)/PCCNW bimodal foam nanocomposites with two species cell sizes have been ready by the solvent casting/particulate leaching methodology in several weight proportion of PCCNWs.
The mechanical, thermal, and in vitro organic properties of PCL/PCCNW nanocomposites have been investigated. All PCL/PCCNW scaffolds have been hydrophilic, biodegradable, and likewise noncytotoxic. The human mesenchymal stem cells have been cultured on the ready PCL/PCCNW bimodal foam nanocomposites and differentiated to osteoblasts.
On the premise of evaluating exams reminiscent of MTT assay, acridine orange/ethidium bromide staining, alkaline phosphatase assay, calcium content material assay, and alizarin purple staining, PCL/PCCNW scaffolds have been launched as an acceptable possibility for emulating the conduct of extracellular matrix. Rising PCCNWs improves the mechanical, hydrophilic, and biodegradability properties of the nanocomposites in addition to their osteoconductivity.
Xanthatin synergizes with cisplatin to suppress homologous recombination by JAK2/STAT4/BARD1 axis in human NSCLC cells
Xanthatin (Xa) is a bicyclic sesquiterpene lactone recognized from the plant Xanthium L. with spectacular antitumor exercise, however the function of Xa in non-small cell lung most cancers (NSCLC) just isn’t recognized. Right here we discovered that Xa inhibits proliferation, migration, invasion and induces apoptosis in NSCLC cells. RNA sequencing and Gene set enrichment evaluation revealed that Xa considerably prompts p53 pathway and suppresses E2F targets, G2M checkpoint and MYC targets in A549 cells.
Amongst these modified genes, the down-regulated gene BARD1 triggered by Xa was recognized as a candidate concerned in Xa’s antitumor impact due to its important function in homologous recombination (HR). Additional research demonstrated that Xa inhibits HR by the BARD1/BRCA1/RAD51 axis, which boosts cell sensitivity to cisplatin. Mechanistic research confirmed that Xa inhibits BARD1 by the JAK2/STAT4 pathway. Our examine revealed that Xa is a promising drug to deal with NSCLC, particularly together with typical chemotherapy.
Evaluation of Picture-Induced Cytotoxic Exercise of Cachrys sicula and Cachrys libanotis Enriched-Coumarin Extracts towards Human Melanoma Cells
Photochemotherapy is without doubt one of the most attention-grabbing present therapeutic approaches for the therapy of melanoma. Totally different courses of naturally occurring phytochemicals demonstrated attention-grabbing photoactive properties. The intention of this examine was to judge the photocytotoxic potential of two Cachrys species from Southern Italy: C. sicula and C. libanotis (Apiaceae).
The enriched-coumarin extracts have been obtained from aerial elements by each conventional maceration and pressurized cyclic solid-liquid (PCSL) extraction utilizing Naviglio extractor®. Qualitative and quantitative analyses of furanocoumarins have been carried out with GC-MS. The photocytotoxic results have been verified on C32 melanoma cells irradiated at a dose of 1.08 J/cm2.
The apoptotic responses have been additionally assessed. Furthermore, phenolic content material and the in vitro antioxidant potential have been estimated. Xanthotoxin, bergapten, and isopimpinellin have been recognized. All of the samples induced concentration-dependent photocytotoxic results (IC50 starting from 3.16 to 18.18 μg/mL). The C. libanotis pattern obtained with Naviglio extractor® was the simplest one (IC50 = 3.16 ± 0.21 μg/mL), adopted by C. sicula pattern obtained with the identical method (IC50 = 8.83 ± 0.20 μg/mL). Each Cachrys samples obtained by PCSL induced up-regulation of apoptotic alerts reminiscent of BAX (Bcl2-associated X protein) and PARP (poly ADP-ribose polymerase) cleavage.
) Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381141-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381141-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381141-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381142-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381142-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381142-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381142-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381142-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381143-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381143-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381143-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381143-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
Langerin/CD207 (Marker of Langerhans Cells) |
|
MBS4381143-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
 (BSA & Azide Free)) CD1a (Langerhans Cells) (BSA & Azide Free) |
|
MBS6268078-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) |
|
MBS6268078-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 Lymphocytes and Langerhans Cells Antibody |
|
abx415072-01mg |
Abbexa |
0.1 mg |
EUR 543.6 |
|
|
Lymphocytes and Langerhans Cells Antibody |
|
abx415072-200l |
Abbexa |
200 µl |
EUR 362.5 |
 (BSA & Azide Free) (AP)) CD1a (Langerhans Cells) (BSA & Azide Free) (AP) |
|
MBS6265836-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (AP) |
|
MBS6265836-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 (BSA & Azide Free) (PE)) CD1a (Langerhans Cells) (BSA & Azide Free) (PE) |
|
MBS6266957-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (PE) |
|
MBS6266957-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
) CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380302-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380302-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380302-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380302-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380302-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380303-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380303-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380303-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380303-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4380303-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381375-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381375-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381375-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381375-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381375-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381376-002mgWithBSAAzideat02mgmL |
MyBiosource |
0.02mg(WithBSA&Azideat0.2mg/mL) |
EUR 230 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381376-01mgWithBSAAzideat02mgmL |
MyBiosource |
0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381376-01mgWithoutBSAAzideat1mgmL |
MyBiosource |
0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 405 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381376-5x01mgWithBSAAzideat02mgmL |
MyBiosource |
5x0.1mg(WithBSA&Azideat0.2mg/mL) |
EUR 1725 |
CD1a/HTA1 (Mature Langerhans Cells Marker) |
|
MBS4381376-5x01mgWithoutBSAAzideat1mgmL |
MyBiosource |
5x0.1mg(WithoutBSA&Azideat1mg/mL) |
EUR 1725 |
 (BSA & Azide Free) (HRP)) CD1a (Langerhans Cells) (BSA & Azide Free) (HRP) |
|
MBS6266732-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (HRP) |
|
MBS6266732-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 (BSA & Azide Free) (APC)) CD1a (Langerhans Cells) (BSA & Azide Free) (APC) |
|
MBS6266060-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (APC) |
|
MBS6266060-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 (BSA & Azide Free) (FITC)) CD1a (Langerhans Cells) (BSA & Azide Free) (FITC) |
|
MBS6266508-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (FITC) |
|
MBS6266508-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 Human Pancreatic Islets of Langerhans Cells |
|
ABC-TC4286 |
AcceGen |
1 vial |
Ask for price |
|
|
|
Description: The Human Pancreatic Islets of Langerhans Cell Culture was derived from Human Pancreas. All donors from which the cells were derived were pre-screened; donors tested negative for the usual blood donation infectious disease panel ABO/RH, Hepatitis B Surface Antigen, HIV1 and 2, Syphilis, hepatitis B Core, Human T Lymphocyte Virus 1 and 2, Hepatitis C Virus, Antibody Screen, Nucleic Amplification Test for HIV 1 HCV, West Nile Virus and Antibodies to Trypanosoma cruzi (the agent of Chagas disease). |
 (BSA & Azide Free) (Biotin)) CD1a (Langerhans Cells) (BSA & Azide Free) (Biotin) |
|
MBS6266284-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (Biotin) |
|
MBS6266284-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
(LGRN/1821), 0.2mg/mL) Langerin / CD207 (Marker of Langerhans Cells)(LGRN/1821), 0.2mg/mL |
|
BNUB1821-100 |
Biotium |
1uL |
EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Langerin / CD207 (Marker of Langerhans Cells)(LGRN/1821), 0.2mg/mL |
|
BNUB1821-500 |
Biotium |
1uL |
EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(LGRN/1821), 1mg/mL) Langerin / CD207 (Marker of Langerhans Cells)(LGRN/1821), 1mg/mL |
|
BNUM1821-50 |
Biotium |
1uL |
EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(LGRN/3136R), 1mg/mL) Langerin / CD207 (Marker of Langerhans Cells)(LGRN/3136R), 1mg/mL |
|
BNUM3136-50 |
Biotium |
1uL |
EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(rLGRN/1821), 1mg/mL) Langerin / CD207 (Marker of Langerhans Cells)(rLGRN/1821), 1mg/mL |
|
BNUM3608-50 |
Biotium |
1uL |
EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(LGRN/3136R), 0.2mg/mL) Langerin / CD207 (Marker of Langerhans Cells)(LGRN/3136R), 0.2mg/mL |
|
BNUB3136-100 |
Biotium |
1uL |
EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Langerin / CD207 (Marker of Langerhans Cells)(LGRN/3136R), 0.2mg/mL |
|
BNUB3136-500 |
Biotium |
1uL |
EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(rLGRN/1821), 0.2mg/mL) Langerin / CD207 (Marker of Langerhans Cells)(rLGRN/1821), 0.2mg/mL |
|
BNUB3608-100 |
Biotium |
1uL |
EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Langerin / CD207 (Marker of Langerhans Cells)(rLGRN/1821), 0.2mg/mL |
|
BNUB3608-500 |
Biotium |
1uL |
EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(), 0.2mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker)(), 0.2mg/mL |
|
BNUB1657-100 |
Biotium |
1uL |
EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
CD1a / HTA1 (Mature Langerhans Cells Marker)(), 0.2mg/mL |
|
BNUB1657-500 |
Biotium |
1uL |
EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(), 1mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker)(), 1mg/mL |
|
BNUM1657-50 |
Biotium |
1uL |
EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
 (BSA & Azide Free) (MaxLight 490)) CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 490) |
|
MBS6267406-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 490) |
|
MBS6267406-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 (BSA & Azide Free) (MaxLight 550)) CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 550) |
|
MBS6267630-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 550) |
|
MBS6267630-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 (BSA & Azide Free) (MaxLight 650)) CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 650) |
|
MBS6267854-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 650) |
|
MBS6267854-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 (BSA & Azide Free) (MaxLight 405)) CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 405) |
|
MBS6267182-01mL |
MyBiosource |
0.1mL |
EUR 1210 |
CD1a (Langerhans Cells) (BSA & Azide Free) (MaxLight 405) |
|
MBS6267182-5x01mL |
MyBiosource |
5x0.1mL |
EUR 5285 |
 Guinea Pig Lymphocytes and Langerhans Cells Antibody |
|
GWB-Q00950 |
GenWay Biotech |
2 ml |
Ask for price |
 MOUSE ANTI GUINEA PIG LYMPHOCYTES AND LANGERHANS CELLS |
|
MBS224794-01mg |
MyBiosource |
0.1mg |
EUR 390 |
MOUSE ANTI GUINEA PIG LYMPHOCYTES AND LANGERHANS CELLS |
|
MBS224794-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1570 |
(C1A/3249), 1mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker)(C1A/3249), 1mg/mL |
|
BNUM3249-50 |
Biotium |
1uL |
EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(C1A/3249), 0.2mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker)(C1A/3249), 0.2mg/mL |
|
BNUB3249-100 |
Biotium |
1uL |
EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
CD1a / HTA1 (Mature Langerhans Cells Marker)(C1A/3249), 0.2mg/mL |
|
BNUB3249-500 |
Biotium |
1uL |
EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
 (C1A/1506R), 0.2mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R), 0.2mg/mL |
|
BNUB1506-100 |
Biotium |
100uL |
EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R), 0.2mg/mL |
|
BNUB1506-500 |
Biotium |
500uL |
EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
 (rC1A/711), 0.2mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), 0.2mg/mL |
|
BNUB1888-100 |
Biotium |
100uL |
EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), 0.2mg/mL |
|
BNUB1888-500 |
Biotium |
500uL |
EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
 (C1A/1506R), 1mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R), 1mg/mL |
|
BNUM1506-50 |
Biotium |
50uL |
EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
(rC1A/711), 1mg/mL) CD1a / HTA1 (Mature Langerhans Cells Marker)(rC1A/711), 1mg/mL |
|
BNUM1888-50 |
Biotium |
1uL |
EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
 (C1A/1506R) Antibody) CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC801506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF680 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC801506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF680 conjugate, Concentration: 0.1mg/mL |
 (rC1A/711) Antibody) CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC801888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF680 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC801888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF680 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC811506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF680R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC811506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF680R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC811888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF680R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC811888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF680R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC051506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF405M conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC051506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF405M conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC051888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF405M conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC051888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF405M conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC431506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF543 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC431506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF543 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC431888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF543 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC431888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF543 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC551506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF555 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC551506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF555 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC551888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF555 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC551888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF555 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC701506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF770 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC701506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF770 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC701888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF770 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC701888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF770 conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC611506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF660R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNC611506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),CF660R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC611888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF660R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNC611888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), CF660R conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNCP1506-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),PerCP conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNCP1888-250 |
Biotium |
250uL |
EUR 472.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), PerCP conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNCR1506-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),RPE conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNCR1888-250 |
Biotium |
250uL |
EUR 472.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), RPE conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNCA1506-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),APC conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNCA1888-250 |
Biotium |
250uL |
EUR 472.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), APC conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNCAP1506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNCAP1506-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNCAP1888-100 |
Biotium |
100uL |
EUR 279.6 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711) Antibody |
|
BNCAP1888-500 |
Biotium |
500uL |
EUR 654 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (rC1A/711), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R) Antibody |
|
BNCH1506-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against CD1a / HTA1 (Mature Langerhans Cells Marker) (C1A/1506R),Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Furthermore, these samples proved to be extra photoactive, giving a better upregulation of p21 protein within the presence of UVA radiation. Obtained outcomes recommend that investigated species could possibly be promising candidates for additional investigations aimed to search out new potential medicine for the photochemotherapy of pores and skin most cancers.
